Loading...
Market
Will BridgeBio's infigratinib complete Phase 3 clinical trials successfully by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and BridgeBio's press releases
Story
BridgeBio's Infigratinib Receives FDA Breakthrough Therapy Designation, Stock Surges 64.2%
Sep 17, 2024, 11:32 AM
BridgeBio Pharma announced that its investigational therapeutic, infigratinib, has been awarded Breakthrough Therapy Designation by the FDA. This marks the first time such a designation has been given to a treatment for achondroplasia. The designation is expected to expedite the development and review of infigratinib, which is being developed as an oral treatment for children with achondroplasia. Following this announcement, BridgeBio's stock ($BBIO) surged by 64.2%.
View original story
Similar markets
Yes • 50%
No • 50%
FDA only • 25%
EMA only • 25%
Both FDA and EMA • 25%
Neither • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
